series-b
Stage
1
Investors
About
A gene therapy company advancing AAV-based therapies for inherited neurological conditions, with a lead program targeting Adrenomyeloneuropathy (AMN).
Explore SwanBio Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.